Pre-symptomatic D-CAA | Symptomatic D-CAA | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
n (CAA/CON) | D-CAA | Controls | p -value | Adjusted p -value | n (CAA/CON) | D-CAA | Controls | p -value | Adjusted p -value | |
Demographics | ||||||||||
Age (y) | 11/22 | 38.0 (31.0–52.0) | 45.2 (36.5–51.3) | p = 0.61 (ns)‡ | - | 12/28 | 58.5 (52.8–65.8) | 60.3 (51.6–65.9) | p = 0.95 (ns)‡ | - |
Sex, M/F (% male) | 11/22 | 8/3 (73%) | 11/11 (50%) | p = 0.28 (ns) | - | 12/28 | 5/7 (41.7%) | 17/11 (60.7%) | p = 0.32 (ns) | - |
CSF parameters | ||||||||||
MMP-2 (ng/mL) | 9/22 | 22.6 (17.8–25.6) | 19.2 (13.2–21.7) | p = 0.04 (*) | p = 0.18 (ns) | 11/28 | 23.3 (19.2–25.8) | 25.8 (20.4–30.4) | p = 0.29 (ns) | p = 0.34 (ns) |
MMP-9 (pg/mL) | 10/21 | 712 (534–1211) | 634 (372–764) | p = 0.19 (ns) | p = 0.62 (ns) | 12/28 | 1019 (657–1561) | 693 (364–1071) | p = 0.17 (ns) | p = 0.66 (ns) |
MMP-14 (ng/mL) | 9/21 | 2.60 (2.20–3.07) | 2.49 (1.95–2.79) | p = 0.31 (ns) | p = 0.98 (ns) | 12/28 | 1.99 (1.76–2.47) | 2.57 (1.99–3.58) | p = 0.03 (*) | p = 0.02 (*) |
TIMP-1 (ng/mL) | 10/22 | 30.6 (20.0–36.1) | 26.0 (20.0–31.3) | p = 0.41 (ns) | p = 0.74 (ns) | 12/28 | 40.2 (27.5–45.9) | 35.2 (27.9–40.3) | p = 0.71 (ns) | p = 0.82 (ns) |
TIMP-2 (ng/mL) | 10/22 | 40.4 (34.2–48.1) | 40.2 (34.1–46.5) | p = 0.67 (ns) | p = 0.66 (ns) | 12/28 | 46.7 (40.2–52.3) | 44.8 (40.7–50.4) | p = 0.68 (ns)‡ | p = 0.71 (ns) |
TIMP-3 (pg/mL) | 10/17 | 87.9 (68.9–116.8) | 50.5 (37.2 – 87.1) | p = 0.09 (ns) | p = 0.15 (ns) | 12/26 | 91.3 (57.6–125.4) | 87.3 (46.0–120.5) | p = 1.00 (ns) ‡ | p = 0.97 (ns) |
Total protein (mg/mL) | 11/22 | 0.71 (0.65–0.84) | 0.75 (0.64–0.80) | p = 0.67 (ns) | p = 0.47 (ns) | 12/28 | 0.84 (0.74–0.94) | 0.83 (0.68–0.92) | p = 0.81 (ns) | p = 0.90 (ns) |